采用ChAdOx1 nCoV-19和BNT162b2进行异源初免-加强免疫接种。 - Suppr

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.

作者信息

Tenbusch Matthias, Schumacher Sofie, Vogel Emanuel, Priller Alina, Held Jürgen, Steininger Philipp, Beileke Stephanie, Irrgang Pascal, Brockhoff Ronja, Salmanton-García Jon, Tinnefeld Kathrin, Mijocevic Hrvoje, Schober Kilian, Bogdan Christian, Yazici Sarah, Knolle Percy, Cornely Oliver A, Überla Klaus, Protzer Ulrike

机构信息

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Universitätsklinikum Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

University Hospital of Cologne, Faculty of Medicine, Department I of Internal Medicine, Cologne, Germany; University of Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.

出版信息

Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.

DOI:10.1016/S1473-3099(21)00420-5

PMID:34332707

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8321428/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3801/8321428/2e8d2c2cbaec/gr1_lrg.jpg

相似文献

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.采用ChAdOx1 nCoV-19和BNT162b2进行异源初免-加强免疫接种。

Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.异源初免-加强型新型冠状病毒肺炎疫苗接种：初始反应原性数据

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.针对 SARS-CoV-2 的三种不同疫苗加强免疫后的抗体反应动力学。

Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study.腺病毒载体 ChAdOx1-S 和 BNT162b2 序贯加强免疫的前瞻性队列研究：反应原性和免疫原性。

Int J Infect Dis. 2023 Mar;128:166-175. doi: 10.1016/j.ijid.2022.12.034. Epub 2022 Dec 30.

Delaying the second dose of covid-19 vaccines.推迟新冠疫苗的第二剂接种。

BMJ. 2021 Mar 18;372:n710. doi: 10.1136/bmj.n710.

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.细胞和体液免疫应答在异源和同源 SARS-CoV-2 疫苗接种中的相互关系。

Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16.

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.异源 ChAdOx1 nCoV-19/mRNA 疫苗接种的免疫原性和反应原性。

Nat Med. 2021 Sep;27(9):1530-1535. doi: 10.1038/s41591-021-01464-w. Epub 2021 Jul 26.

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？

Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。

Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.

引用本文的文献

Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants.异源初免-加强免疫接种可驱动基质激活和针对新冠病毒变异株的适应性免疫。

Front Immunol. 2025 May 28;16:1597417. doi: 10.3389/fimmu.2025.1597417. eCollection 2025.

Frequency of SARS-CoV-2 Infections among Healthcare Workers in Germany: 3-Year Follow-Up Study.德国医护人员中新型冠状病毒2型感染的频率：3年随访研究

Infect Dis Rep. 2024 Jul 19;16(4):615-627. doi: 10.3390/idr16040047.

Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study.2022 年 12 月 7 日中国结束“零新冠”政策后不久儿童感染 SARS-CoV-2 的发生率：一项横断面、多中心、血清流行病学研究。

Front Public Health. 2023 Nov 9;11:1283158. doi: 10.3389/fpubh.2023.1283158. eCollection 2023.

B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity.B 细胞和抗体对 SARS-CoV-2 的反应：感染、疫苗接种和混合免疫。

Cell Mol Immunol. 2024 Feb;21(2):144-158. doi: 10.1038/s41423-023-01095-w. Epub 2023 Nov 10.

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.异源加强免疫 PastoCovac Plus 对 ChAdOx1-S 或 BBIBP-CorV 初免个体的 COVID-19 免疫原性和安全性。

PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.

Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.统计解释 4 剂 COVID-19 疫苗在普通人群中的保护作用。

Front Public Health. 2023 Sep 22;11:1253762. doi: 10.3389/fpubh.2023.1253762. eCollection 2023.

A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers.医护人员群体中SARS-CoV-2疫苗诱导的抗S-RBD-Ig反应的系统评价

Vaccines (Basel). 2023 Sep 7;11(9):1467. doi: 10.3390/vaccines11091467.

Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.2 型糖尿病患者加强免疫后对灭活 COVID-19 疫苗的抗体反应。

J Diabetes. 2023 Nov;15(11):931-943. doi: 10.1111/1753-0407.13448. Epub 2023 Jul 30.

Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People.快速抗体检测在无家可归者中 COVID-19 疫苗的有效性。

Viruses. 2023 Jun 20;15(6):1400. doi: 10.3390/v15061400.

COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.COVID-19 腺病毒载体疫苗接种可引发强大的记忆 B 细胞反应，具有识别奥密克戎 BA.2 和 BA.5 变异株的能力。

J Clin Immunol. 2023 Oct;43(7):1506-1518. doi: 10.1007/s10875-023-01527-2. Epub 2023 Jun 16.

本文引用的文献

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.BNT162b2 加强剂在 ChAdOx1-S 初免参与者中的免疫原性和反应原性（CombiVacS）：一项多中心、开放标签、随机、对照、2 期临床试验。

Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。

Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.美国 2021 年 4 月：在报告接种强生（Johnson & Johnson）新冠疫苗的人群中出现血栓性血小板减少综合征后，免疫实践咨询委员会更新了强生疫苗的使用建议。

MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.接种 ChAdOx1 nCoV-19 疫苗后对血小板因子 4 的病理性抗体。

N Engl J Med. 2021 Jun 10;384(23):2202-2211. doi: 10.1056/NEJMoa2105385. Epub 2021 Apr 16.

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。

N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献